Glutathione in Childhood Acute Leukaemias
Part of the
Advances in Experimental Medicine and Biology
book series (AEMB, volume 457)
In order to test the hypothesis that glutathione (GSH) is an important determinant of treatment response in childhood acute leukaemia, blast cell GSH levels were studied in a cohort of children with acute lymphoblastic (ALL) and acute myeloid (AML) leukaemia.
In both ALL and AML, several indicators of poor prognosis are well established but the underlying molecular mechanisms leading to resistant disease are still poorly understood. GSH is an intracellular thiol implicated in the development of cytotoxic drug resistance and appears to be involved in the control of cell proliferation and apoptosis.
In this study, total GSH was measured in cryopreserved blasts from 62 childhood ALL and 13 AML patients. In ALL, high GSH levels were associated with a relatively poor prognosis. A positive correlation was demonstrated between the GSH level and presenting white cell count (WCC). GSH levels were significantly higher in T lineage ALL compared with B lineage and in AML blasts compared with ALL.
These results are supportive of GSH as prognostic indicator in childhood leukaemia and may suggest one mechanism of treatment failure. They imply that it may be possible to improve chemosensitivity by the use of known modulators of GSH synthesis.
KeywordsGlutathione childhood leukaemia prognostic indicators drug resistance
Cotes J.E., Kantarjian H.M. Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. Cancer, 1995, 76, 2393–2417.CrossRefGoogle Scholar
Pieters R., Huismans D.R., Loonen A. H., Hahien K., Van Der Does-Van Den Berg A., Van Wering E.R. and Veerman A. J. P. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet, 1991, 338, 399–403.PubMedCrossRefGoogle Scholar
O’Brien M.L. and Tew K.D. Glutathione and related enzymes in multidrug resistance. Eur. J. Cancer, 1996, 967–978.Google Scholar
Frischer H., Kennedy E J., Chigurupati R. and Sivarajan M. Glutathione, cell proliferation, and l,3-bis-(2-chloroethyl)-1-nitrosourea in K562 leukemia. Journal of Clinical Investigation, 1993, 92, 2761–2767.PubMedCrossRefGoogle Scholar
Watson R. W. G., Rotstein O. D., Nathens A.B., Dackiw A.P.B. and Marshall J. C. Thiol-mediated redox regulation of neutrophil apoptosis. Surgery, 1996, 120, 150–158.PubMedCrossRefGoogle Scholar
Ozols R.F., O’Dwyer P.J., Hamilton T.C. and Young R. C. The role of glutathione in drug resistance. Cancer Treat. Rev., 1990, 17, 45–50.PubMedCrossRefGoogle Scholar
Ferraris A. M., Rolfo M., Mangerini R. and Gaetani G. F. Increased glutathione in chronic lymphocytic leukemia lymphocytes, Am. J. Hematol., 1994, 47, 237–238.PubMedCrossRefGoogle Scholar
Maung Z. T., Reid M. M., Matheson E., Taylor P. R. A., Proctor S. J. and Hall A. G. Corticosteroid resistance is increased in lymphoblasts from adults compared with children: Preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia. Br. J. Haematol., 1995, 91, 93–100.PubMedCrossRefGoogle Scholar
Paydas S., Yuregir G. T., Sahin B., Seyrek E. and Burgut R. Intracellular glutathione content in leukemias. Oncology, 1995, 52, 112–115.PubMedCrossRefGoogle Scholar
Kearns P. R. and Hall A. G. Microtitre plate technique for the measurement of glutathione in fresh and cryopreserved lymphoblasts using the enzyme recycling method. Methods in Molecular Medicine, 1999, (in press).Google Scholar
Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal. Biochem., 1976, 72, 248–254.PubMedCrossRefGoogle Scholar
Terradez P., Asensi M., Lasso della Vega M. C., Puertes I. R., Vina J. and Estrela J. M. Depletion of tumour glutathione in vivo
by buthionine sulphoximine: Modulation by the rate of cellular proliferation and inhibition of cancer growth. Biochem. J., 1993, 292, 477–483.PubMedGoogle Scholar
Poot M., Teubert H., Rabinovitch P. S. and Kavanagh T. J. De novo synthesis of glutathione is required for both entry into and progression through the cell cycle. J. Cell. Physiol., 1995, 163, 555–560.PubMedCrossRefGoogle Scholar
Frischer H., Kennedy E. J., Chigurupati R. and Sivarajan M. Glutathione, cell proliferation, and 1,3-bis-(2-chloroethyl)-1-nitrosourea in K562 leukemia. J. Clin. Invest., 1993, 92, 2761–2767.PubMedCrossRefGoogle Scholar
Kavanagh T. J., Grossmann A., Jaecks E. P., Jinneman J. C., Eaton D. L., Martin G. M. and Rabinovitch P. S. Proliferative capacity of human peripheral blood lymphocytes sorted on the basis of glutathione content. J. Cell. Physiol., 1990, 145, 472–480.PubMedCrossRefGoogle Scholar
Ngo E. O. and Nutter L. M. Status of glutathione and glutathione-metabolizing enzymes in menadione-resistant human cancer cells. Biochem. Pharmacol., 1994, 47, 421–424.PubMedCrossRefGoogle Scholar
Scarffe J. H., Hann I. M., Evans D. I. K., Morris-Jones P., Palmer M. K., Lilleyman J. S. and Crowther D. Relationship between the pretreatment proliferative activity of marrow blast cells and prognosis of acute lymphoblastic leukaemia of childhood. Br. J. Cancer, 1980, 41, 764–771.PubMedCrossRefGoogle Scholar
Siemann D. W. and Beyers K. L. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy. British Journal of Cancer, 1993, 68, 1071–1079.PubMedCrossRefGoogle Scholar
Medh R. D., Gupta V. and Awasthi Y. C. Reversal of melphalan resistance in vivo and in vitro by modulation of glutathione metabolism. Biochem Pharmacol., 1991, 42, 439–441.PubMedCrossRefGoogle Scholar
Ozols R. F., Louie K. G., Plowman J., Behrens B. C., Fine R. L., Dykes D. and Hamilton T. C. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol., 1987, 36, 147–153.PubMedCrossRefGoogle Scholar
O’Dwyer P. J., Hamilton T. C., Young R. C., LaCreta F. P., Carp N., Tew K. D., Padavic K., Comis R. L. and Ozols R. F. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J. Natl. Cancer Inst., 1992, 84, 264–267.PubMedCrossRefGoogle Scholar
© Springer Science+Business Media New York 1999